Gilead Sciences expanded a partnership to co-develop next-generation CAR-T cell therapies.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences expanded a partnership to co-develop next-generation CAR-T cell therapies.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
Arcellx
Biotechnology Company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyArcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial We recently published 11 Best Cancer Stocks to Buy Right Now. Arcellx, Inc. stands sixth among them. Arcellx, Inc. (NASDAQ:ACLX) is a bio